AURA
Aura Biosciences, Inc.·Healthcare
6.80
0.295%(+0.02)
Market ClosedLast Updated: — ET
52W L: $4.3452W H: $7.48
AURA NEWS
zacks.com
21h ago
Aura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy?
Aura Biosciences, Inc. (AURA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, AURA's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
zacks.com
4d ago
Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year?
Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
zacks.com
Apr 2
Wall Street Analysts Predict a 201.49% Upside in Aura Biosciences (AURA): Here's What You Should Know
The mean of analysts' price targets for Aura Biosciences (AURA) points to a 201.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
globenewswire.com
Mar 30
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability Completed with New Formulation with Potential Across Non-ocular Solid Tumor Indications, Beginning with Urologic Oncology BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights. “2025 has been a year of focused execution across our clinical portfolio, with significant progress in trial enrollment, highlighted by the acceleration of our global Phase 3 CoMpass trial in early choroidal melanoma and continued enrollment in our Phase 1b/2 NMIBC trial,” said Elisabet de los Pinos, Ph.D.
defenseworld.net
Mar 27
Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Rating of “Hold” by Brokerages
Shares of Aura Biosciences, Inc. (NASDAQ: AURA - Get Free Report) have been assigned an average rating of "Hold" from the five brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to
zacks.com
Mar 20
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?
Here is how Aura Biosciences, Inc. (AURA) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.
